Literature DB >> 19438742

Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Yukio Takeshima1, Vishwa J Amatya, Kei Kushitani, Mayumi Kaneko, Kouki Inai.   

Abstract

AIMS: The differential diagnosis of pleural sarcomatoid mesothelioma (SM) from lung sarcomatoid carcinoma (LSC) invading parietal pleura and chest wall is a challenging issue. The aim of this study was to identify useful antibodies that can be used for the differential diagnosis of pleural SM from LSC. METHODS AND
RESULTS: Forty-five cases of pleural SM and 27 cases of LSC were immunohistochemically analysed by using 15 commercially available antibodies, including D2-40 and antibodies to calretinin, thrombomodulin, Wilms' Tumour 1, carcinoembryonic antigen (CEA), Napsin A, thyroid transcription factor (TTF)-1, pan-cytokeratin, CAM5.2, epithelial membrane antigen, Ber-EP4, MOC-31, alpha-smooth muscle actin, h-caldesmon and desmin. The results revealed that D2-40 positivity was significantly higher in pleural SM (86.7%) than in LSC (25.9%). The positivity of the adenocarcinoma markers, including CEA, Napsin A, and TTF-1, was low even in LSC.
CONCLUSIONS: Evaluating the positivity and degree of staining of the well-known mesothelial marker D2-40 could be applied to differentiate pleural SM from the sarcomatoid component of LSC, in addition to assessing clinical and radiological information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438742     DOI: 10.1111/j.1365-2559.2009.03298.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.

Authors:  Zheng Hua Piao; Xin Cheng Zhou; Jia Yi Chen
Journal:  Virchows Arch       Date:  2021-02-11       Impact factor: 4.064

3.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

4.  MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Authors:  Vishwa Jeet Amatya; Kei Kushitani; Amany Sayed Mawas; Yoshihiro Miyata; Morihito Okada; Takumi Kishimoto; Kouki Inai; Yukio Takeshima
Journal:  Mod Pathol       Date:  2017-01-27       Impact factor: 7.842

5.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

Review 6.  Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.

Authors:  Weiquan Zhang; Xinshu Wu; Licun Wu; Weidong Zhang; Xiaogang Zhao
Journal:  Ann Transl Med       Date:  2015-08

7.  Localized malignant pleural sarcomatoid mesothelioma misdiagnosed as benign localized fibrous tumor.

Authors:  Kwan-Chang Kim; Hong-Phuc Vo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.

Authors:  Francoise Galateau Salle; Nolwenn Le Stang; Franck Tirode; Pierre Courtiol; Andrew G Nicholson; Ming-Sound Tsao; Henry D Tazelaar; Andrew Churg; Sanja Dacic; Victor Roggli; Daniel Pissaloux; Charles Maussion; Matahi Moarii; Mary Beth Beasley; Hugues Begueret; David B Chapel; Marie Christine Copin; Allen R Gibbs; Sonja Klebe; Sylvie Lantuejoul; Kazuki Nabeshima; Jean-Michel Vignaud; Richard Attanoos; Luka Brcic; Frederique Capron; Lucian R Chirieac; Francesca Damiola; Ruth Sequeiros; Aurélie Cazes; Diane Damotte; Armelle Foulet; Sophie Giusiano-Courcambeck; Kenzo Hiroshima; Veronique Hofman; Aliya N Husain; Keith Kerr; Alberto Marchevsky; Severine Paindavoine; Jean Michel Picquenot; Isabelle Rouquette; Christine Sagan; Jennifer Sauter; Francoise Thivolet; Marie Brevet; Philippe Rouvier; William D Travis; Gaetane Planchard; Birgit Weynand; Thomas Clozel; Gilles Wainrib; Lynnette Fernandez-Cuesta; Jean-Claude Pairon; Valerie Rusch; Nicolas Girard
Journal:  J Thorac Oncol       Date:  2020-03-09       Impact factor: 15.609

Review 9.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

10.  Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma.

Authors:  Go Makimoto; Keiichi Fujiwara; Nobukazu Fujimoto; Ichiro Yamadori; Toshio Sato; Takumi Kishimoto
Journal:  Case Rep Oncol       Date:  2014-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.